Novo Nordisk shares fell 13% in US premarket and Copenhagen trade after its obesity drug CagriSema failed to match Eli Lilly’s tirzepatide in trial.
Novo Nordisk shares fell 13% in US premarket and Copenhagen trade after its obesity drug CagriSema failed to match Eli Lilly’s tirzepatide in trial.